Not able to attend ECTRIMS this year? You can catch up with all the action from today with our daily video, best of social media and poster highlights.
Browsing: demyelinating disease
Today was the second day of ECTRIMS, with more fascinating talks and exciting posters. You can catch up on the highlights and headlines in our daily update.
Today was the first day of ECTRIMS 2018 and we’re excited to be attending! You can find a daily video update, photos from the day, poster highlights and more in our daily updates.
A team from Cleveland Clinic (OH, USA) has identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.
The second and final installment of our discussion focuses on the use of stem cells and what further research is on the horizons for multiple sclerosis.
Ask the Experts: Emerging therapies in multiple sclerosis (Part I: mechanisms, therapies and challenges)
In the first installment of this discussion, our experts discuss the mechanisms, therapies and challenges involved in multiple sclerosis research.
To mark World Multiple Sclerosis Day, we’re taking the opportunity to look back on some of the highlights in the field so far this year.
Alexander Rae-Grant chats to Lauren Pulling about the new guideline for multiple sclerosis treatment and how it will affect treatment practice in the field.
Results from the Phase III EXPAND study of siponimod in secondary progressive multiple sclerosis have been announced, revealing that the drug reduced the risk of disability progression.